CN110225752B - 用作gpr120调节器的单环化合物 - Google Patents

用作gpr120调节器的单环化合物 Download PDF

Info

Publication number
CN110225752B
CN110225752B CN201780068713.3A CN201780068713A CN110225752B CN 110225752 B CN110225752 B CN 110225752B CN 201780068713 A CN201780068713 A CN 201780068713A CN 110225752 B CN110225752 B CN 110225752B
Authority
CN
China
Prior art keywords
compound
preparation
lcms
esi
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780068713.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110225752A (zh
Inventor
布里安·雷蒙多
埃莱娜·S·科尔通
约翰·格里芬
埃里克·施坦格兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Overall Health
Original Assignee
Overall Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Overall Health filed Critical Overall Health
Publication of CN110225752A publication Critical patent/CN110225752A/zh
Application granted granted Critical
Publication of CN110225752B publication Critical patent/CN110225752B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780068713.3A 2016-09-12 2017-09-11 用作gpr120调节器的单环化合物 Active CN110225752B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662393616P 2016-09-12 2016-09-12
US62/393,616 2016-09-12
PCT/US2017/050956 WO2018049324A1 (en) 2016-09-12 2017-09-11 Monocyclic compounds useful as gpr120 modulators

Publications (2)

Publication Number Publication Date
CN110225752A CN110225752A (zh) 2019-09-10
CN110225752B true CN110225752B (zh) 2023-05-05

Family

ID=61562455

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780068713.3A Active CN110225752B (zh) 2016-09-12 2017-09-11 用作gpr120调节器的单环化合物

Country Status (7)

Country Link
US (3) US10800773B2 (enExample)
EP (1) EP3509587B1 (enExample)
JP (1) JP7086942B2 (enExample)
KR (1) KR102537985B1 (enExample)
CN (1) CN110225752B (enExample)
CA (1) CA3041033A1 (enExample)
WO (1) WO2018049324A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110225752B (zh) 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
US10865201B2 (en) * 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators
WO2019202612A2 (en) * 2018-04-20 2019-10-24 Krish Biotech Research Private Limited Method of treatment of non-alcoholic steatohepatitis, nash
US11142525B2 (en) * 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
IL297838A (en) 2020-05-01 2023-01-01 Pfizer Azalactam compounds as hpk1 inhibitors
US20230219927A1 (en) * 2020-05-08 2023-07-13 Georgiamune Llc Akt3 modulators
CN114671827B (zh) * 2020-12-24 2024-09-20 杭州百新生物医药科技有限公司 邻苯甲酰磺酰亚胺类衍生物及其应用
KR102605163B1 (ko) * 2021-06-01 2023-11-23 연세대학교 산학협력단 뇌암의 예방 또는 치료용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110312976A1 (en) * 2009-03-11 2011-12-22 Msd K.K. Novel isoindolin-1-one derivative
JP2014533736A (ja) * 2011-11-30 2014-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規二環式ジヒドロイソキノリン−1−オン誘導体
WO2014209034A1 (en) * 2013-06-27 2014-12-31 Lg Life Sciences Ltd. Biaryl derivatives as gpr120 agonists
US20150274672A1 (en) * 2012-10-11 2015-10-01 Merck Sharp & Dohme Corp. Substituted spiropiperidinyl compounds useful as gpr120 agonists
JP2016141618A (ja) * 2015-01-29 2016-08-08 国立大学法人金沢大学 脱水縮合剤

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2735225A (en) * 1956-02-21 Table ix p petri dish tests with x-phthalimido-
DE2253251A1 (de) 1972-10-30 1974-05-09 Thomae Gmbh Dr K Neue phthalimido-sulfonylharnstoffe
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4165435A (en) * 1976-06-25 1979-08-21 Ciba-Geigy Corporation Fire retardant s-triazine derivatives
DE3474547D1 (en) 1983-12-02 1988-11-17 Shell Int Research Diphenyl ether herbicides
FR2659327A1 (fr) * 1990-03-08 1991-09-13 Centre Nat Rech Scient Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69224115T2 (de) 1991-07-30 1998-08-20 Ciba Geigy Ag Heteroaryl substituierte Hydroxylaminderivate als Lipoxygenase-Inhibitoren
US5350761A (en) 1991-07-30 1994-09-27 Ciba-Geigy Corporation Indolyl substituted hydroxylamine derivatives
TW219935B (enExample) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
PT891332E (pt) * 1996-03-29 2004-07-30 Pfizer Derivados de 6-fenilpiridil-2-amina
US6716836B2 (en) 2001-03-22 2004-04-06 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors
GB0124627D0 (en) 2001-10-15 2001-12-05 Smithkline Beecham Plc Novel compounds
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
EP1688138A4 (en) 2003-11-26 2008-01-16 Takeda Pharmaceutical AGENT FOR REGULATING THE FUNCTION OF A RECEIVER
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N型カルシウムチャネル阻害薬
US8110681B2 (en) 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
AU2007326395B2 (en) 2006-12-01 2012-10-11 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
MY150746A (en) 2006-12-27 2014-02-28 Sanofi Aventis Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
JP5175866B2 (ja) 2007-02-22 2013-04-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Gタンパク質共役受容体を調節するための化合物および方法
KR20090113382A (ko) 2007-02-22 2009-10-30 아이알엠 엘엘씨 G 단백질-커플링된 수용체의 조절제로서의 티아졸 유도체
US8318781B2 (en) 2007-04-26 2012-11-27 Japan Science And Technology Agency G-protein-conjugated receptor agonist
KR101511396B1 (ko) 2007-07-20 2015-04-13 추가이 세이야쿠 가부시키가이샤 p27 단백질 유도제
JPWO2009147990A1 (ja) 2008-06-02 2011-10-27 Msd株式会社 新規イソオキサゾール誘導体
JP2012506386A (ja) 2008-10-21 2012-03-15 メタボレックス, インコーポレイテッド アリールgpr120受容体アゴニストおよびその使用
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
US8314120B2 (en) 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
EP2582674B1 (en) 2010-06-16 2014-10-01 Cymabay Therapeutics, Inc. Gpr120 receptor agonists and uses thereof
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CA2841757A1 (en) 2011-07-15 2013-01-24 Etzer Darout Gpr 119 modulators
WO2013139341A1 (en) 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
KR101942752B1 (ko) 2012-11-05 2019-01-28 주식회사 엘지화학 Gpr120 효능제로서의 티오아릴 유도체
RU2015123982A (ru) 2012-12-03 2017-01-13 Ф. Хоффманн-Ля Рош Аг Соединения замещенных триазола и имидазола
US9714252B2 (en) 2012-12-20 2017-07-25 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
CA2905729C (en) 2013-03-14 2021-11-09 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of gpr120
CA2905428A1 (en) 2013-03-14 2014-10-02 Bristol-Myers Squibb Company Bicyclo [2.2.1] acid gpr120 modulators
WO2014159054A1 (en) 2013-03-14 2014-10-02 Janssen Pharmaceutica Nv Gpr120 agonists for the treatment of type ii diabetes
EP2970157B1 (en) 2013-03-14 2018-04-25 Janssen Pharmaceutica NV Benzo-fused heterocyclic derivatives useful as agonists of gpr120
US8962660B2 (en) 2013-03-14 2015-02-24 Bristol-Myers Squibb Company Oxabicyclo [2.2.2] acid GPR120 modulators
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
AR100328A1 (es) * 2014-05-07 2016-09-28 Bristol Myers Squibb Co Moduladores pirrolidina de gpr40
JP2017527559A (ja) 2014-08-29 2017-09-21 シーエイチディーアイ ファウンデーション,インコーポレーテッド ハンチントンタンパク質のイメージング用プローブ
ES2989326T3 (es) 2015-10-21 2024-11-26 Otsuka Pharma Co Ltd Compuestos de benzolactama como inhibidores de la proteína cinasa
CN110225752B (zh) 2016-09-12 2023-05-05 整体健康 用作gpr120调节器的单环化合物
US10865201B2 (en) 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110312976A1 (en) * 2009-03-11 2011-12-22 Msd K.K. Novel isoindolin-1-one derivative
JP2014533736A (ja) * 2011-11-30 2014-12-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規二環式ジヒドロイソキノリン−1−オン誘導体
US20150274672A1 (en) * 2012-10-11 2015-10-01 Merck Sharp & Dohme Corp. Substituted spiropiperidinyl compounds useful as gpr120 agonists
WO2014209034A1 (en) * 2013-06-27 2014-12-31 Lg Life Sciences Ltd. Biaryl derivatives as gpr120 agonists
JP2016141618A (ja) * 2015-01-29 2016-08-08 国立大学法人金沢大学 脱水縮合剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Synthesis and structural investigation of N-pyridyl-1, 3-dihydroxyisoindolines";Jasim Al-Rawi等;《Asian Journal of Chemistry》;19910131;第3卷(第1期);第30-37页,尤其是第30-31页化合物2部分 *
"Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials";Neil R. Norcross等;《Journal of Medicinal Chemistry》;20160617;第6101-6120页,尤其是 *
RN:1334634-35-3;CHEMICAL ABSTRACTS SERVICE;《STN Registry数据库》;20111007 *
RN:1440520-62-6;CHEMICAL ABSTRACTS SERVICE;《STN Registry数据库》;20130624 *
RN:1935530-23-6;CHEMICAL ABSTRACTS SERVICE;《STN Registry数据库》;20160620 *

Also Published As

Publication number Publication date
US12116362B2 (en) 2024-10-15
CN110225752A (zh) 2019-09-10
CA3041033A1 (en) 2018-03-15
JP2019530674A (ja) 2019-10-24
KR20190067174A (ko) 2019-06-14
US11548886B2 (en) 2023-01-10
US20190202821A1 (en) 2019-07-04
KR102537985B1 (ko) 2023-05-30
EP3509587A1 (en) 2019-07-17
EP3509587C0 (en) 2023-12-06
WO2018049324A1 (en) 2018-03-15
US20230183231A1 (en) 2023-06-15
EP3509587A4 (en) 2020-03-11
US10800773B2 (en) 2020-10-13
JP7086942B2 (ja) 2022-06-20
EP3509587B1 (en) 2023-12-06
US20210101896A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
CN110225752B (zh) 用作gpr120调节器的单环化合物
US11919891B2 (en) Bicyclic compounds useful as GPR120 modulators
US11447453B2 (en) Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
JP4667867B2 (ja) 置換フロ[2,3−b]ピリジン誘導体
US20070149547A1 (en) Bipyridyl amides as modulators of metabotropic glutamate receptor-5
JP2009533410A (ja) Gタンパク質共役型受容体(gpr119)アゴニストとしてのアゼチジン誘導体
US10369146B2 (en) Phenyl linked quinolinyl modulators of RORγt
JP4092732B2 (ja) ブラジキニン作動薬としてのキノリンおよびベンズイミダゾール誘導体
CN116438174B (zh) 化合物及其作为mif抑制剂的用途
CA3041038C (en) Bicyclic compounds useful as gpr120 modulators
HK40005332B (en) Monocyclic compounds useful as gpr120 modulators
HK40005332A (en) Monocyclic compounds useful as gpr120 modulators
HK40005335A (en) Bicyclic compounds useful as gpr120 modulators
HK40005335B (en) Bicyclic compounds useful as gpr120 modulators
TW202428265A (zh) Kit抑制劑、化合物、醫藥組合物、及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200909

Address after: Massachusetts, USA

Applicant after: Overall health

Address before: California, USA

Applicant before: NUMERATE, Inc.

GR01 Patent grant
GR01 Patent grant